The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.
11d
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an ...
CAMBRIDGE, MA / ACCESS Newswire / March 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Australian Therapeutic Goods Administration (TGA) has granted approval for mRESVIA® (mRNA-1345), ...
While U.S. policymakers are scaling back funding on mRNA vaccine research, Australia is accelerating investment in the technology. At the center of this effort is Moderna Inc., which is establishing ...
The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback